Press Releases
Date Title and Summary View
Nov 6, 2014 SUNNYVALE, Calif., Nov. 6, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA from December 6 - 9, 2014. IMBRUVICA clinical and pre-clinical dat...
Nov 4, 2014 SUNNYVALE, Calif., Nov. 4, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014, as well as commercial, regulatory and clinical updates. Key Highlights Net product revenue increased by 29% to $142 million, from $109 m...
Nov 4, 2014 LONDON and SUNNYVALE, Calif., Nov. 4, 2014 /PRNewswire/ -- AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers. The collaboration will explore separate combinations of two different Astr...
Nov 4, 2014 LONDON and SUNNYVALE, Calif., Nov. 4, 2014 /PRNewswire/ -- AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. The collaboration will evaluate the efficacy and safety of IMBRUVICA® (ibrutinib), Pharm...
Nov 4, 2014 LONDON, SUNNYVALE, Calif. and RARITAN, N.J., Nov. 4, 2014 /PRNewswire/ -- AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development LLC ("Janssen") today announced they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in ...
Oct 28, 2014 SUNNYVALE, Calif., Oct. 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the third quarter of 2014 on Tuesday, November 4, 2014 at 4:30 P.M. Eastern Time. The financial results for the third quarter of 2014 will be released after ma...
Oct 20, 2014 SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA® (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM)...
Oct 17, 2014 SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the European Commission (EC) has granted marketing approval for IMBRUVICA® (ibrutinib) throughout the 28 member states of the European Union (EU). IMBRUVICA, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to...
Oct 16, 2014 SUNNYVALE, Calif., Oct. 16, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has entered into a master clinical drug supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to evaluate the safety, tolerability and preliminary efficacy of IMBRUVICA® (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor, i...
Oct 13, 2014
PDF
Add to Briefcase
1
... NextLast
Add to Briefcase = add release to Briefcase